Pavmed Inc (Pavmed) is a medical device company. It offers disposable infusion pumps, short-term catheters, percutaneous and tissue ablation devices, and long-term vascular access devices. Its products pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Pavmed’s product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; Caldus, a disposable tissue ablation device; EsoCheck, is a cell collection device; and EsoGuard, is an esophageal DNA test. The company has operations across US. Pavmed is headquartered in New York City, New York, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Pavmed Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Pavmed Inc Company Overview
Pavmed Inc Company Snapshot
Pavmed Inc Pipeline Products and Ongoing Clinical Trials Overview
Pavmed Inc – Pipeline Analysis Overview
Pavmed Inc - Key Facts
Pavmed Inc - Major Products and Services
Pavmed Inc Pipeline Products by Development Stage
Pavmed Inc Ongoing Clinical Trials by Trial Status
Pavmed Inc Pipeline Products Overview
Caldus - Renal Denervation
Caldus - Renal Denervation Product Overview
Caldus - Traditional Tissue Ablation
Caldus - Traditional Tissue Ablation Product Overview
Non-Invasive Diagnostic Test - BE Progression Product Overview
PortIO Device - Next Generation
PortIO Device - Next Generation Product Overview
PortIO Intraosseous Infusion System
PortIO Intraosseous Infusion System Product Overview
PortIO Intraosseous Infusion System Clinical Trial
Pavmed Inc - Key Competitors
Pavmed Inc - Key Employees
Pavmed Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Pavmed Inc, Recent Developments
Aug 14, 2023: Lucid Diagnostics Provides Business Update and Second Quarter Financial Results
Jun 02, 2023: Pavmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot’s Cancerx Partnership as Founding Member
May 16, 2023: PAVmed provides business update and Q1 financial results
May 15, 2023: Lucid Diagnostics provides business update and Q1 financial results
May 05, 2023: Lucid Diagnostics to hold a business update conference call and webcast on May 16, 2023
May 05, 2023: PAVmed to hold a business update conference call and webcast on May 17, 2023
Apr 19, 2023: PAVmed Digital Health subsidiary, Veris Health, to present comprehensive meta-analysis on impact of remote patient monitoring in oncology at HIMSS
Mar 14, 2023: PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results
Mar 13, 2023: Lucid Diagnostics Provides Business Update and Fourth Quarter and Full Year 2022 Financial Results
Feb 28, 2023: PAVmed Digital Health subsidiary Veris Health''s Veris Cancer Care Platform goes live
Table 22: EsoGuard Test - A Multicenter Case-control Study of the Efficacy of EsoGuard on Samples Collected Using EsoCheck, Versus Esophagogastroduodenoscopy, for the Diagnosis of Barrett's Esophagus with and without Dysplasia, and for Esophageal Adenocarcinoma
Table 23: EsoGuard Test - A Multicenter, Prospective, Open-label Registry Study to Capture Real-world Data on Esoguard Testing in at-risk Patients for the Detection of Barrett's Esophagus or Esophageal Adenocarcinoma
Table 24: EsoGuard Test - Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett's Esophagus in At Risk Population (ASBE) A Randomized Controlled, Virtual Patient Trial
Table 25: EsoGuard Test - CLUE: CLinical Utility Study of EsoGuard on Samples Collected Using EsoCheck as a Triage Test for Endoscopy to Identify Barrett's Esophagus (BE)
Table 26: EsoGuard Test - Detection of Barrett s Esophagus in Patients Without Gastroesophageal Reflux Disease (GERD) Symptoms
Table 27: EsoGuard Test - Genetic and Environmental Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Table 28: FlexMo - Product Status
Table 29: FlexMo - Product Description
Table 30: Gen2 EsoCheck Balloon Sampling Device - Product Status
Table 38: Non-Invasive Diagnostic Test - BE Progression - Product Status
Table 39: Non-Invasive Diagnostic Test - BE Progression - Product Description
Table 40: PortIO Device - Next Generation - Product Status
Table 41: PortIO Device - Next Generation - Product Description
Table 42: PortIO Intraosseous Infusion System - Product Status
Table 43: PortIO Intraosseous Infusion System - Product Description
Table 44: PortIO Intraosseous Infusion System - A First-in-human Clinical Safety Study of PortIO Implantation in Patients Requiring Infusion of Fluids or Medications
Table 45: PortIO Intraosseous Infusion System - First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System to Evaluate Safety and Performance
Table 46: Pavmed Inc, Key Employees
Table 47: Pavmed Inc, Subsidiaries
Table 48: Glossary
List of Figures
Figure 1: Pavmed Inc Pipeline Products by Equipment Type
Figure 2: Pavmed Inc Pipeline Products by Development Stage
Figure 3: Pavmed Inc Ongoing Clinical Trials by Trial Status